Scalper1 News
An FDA advisory committee voted in favor of approving Amgen’s (AMGN) cholesterol drug Repatha Wednesday afternoon, but voiced similar concerns as it did for Regeneron’s (REGN) and Sanofi’s (SNY) fellow PCSK9 inhibitor Tuesday. Still, Amgen stock was up about 1% in after-hours trading Wednesday after rising a fraction in the regular session. The panel voted 11-4 in favor of approving Repatha for patients with heterozygous familial Scalper1 News
Scalper1 News